An interventional study of Control Formula and Experimental Formula 1 in Infant Nutritional Physiological Phenomena, Infant Formula and Infant Health, sponsored by Société des Produits Nestlé (SPN). Recruiting at 5 sites in 2 countries. Open to participants aged 0 Days to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.
Société des Produits Nestlé (SPN) is the lead sponsor of 324 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTRL, an infant formula with minimum protein content of 1.8g intact protein/100kcal
Other: Control Formula
EXPL1, an infant formula with minimum protein content of 1.9g hydrolyzed protein/100kcal
Other: Experimental Formula 1
EXPL2, an infant formula identical to EXPL1 but manufactured using a different partially hydrolyzed milk protein base
Other: Experimental Formula 2
Infant formula made with intact protein - minimum 1.8g protein/100kcal
Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
Difference in growth in first 4 months of life between control and experimental groups
To demonstrate that growth from enrollment to age 4 months of infants fed experimental formula 1 (EXPL1) or experimental formula 2 (EXPL2) is non-inferior to that of infants fed control formula (CTRL). This is measured by weight gain velocity (g/day).
Time frame: From enrollment to age 4 months
Equivalence in growth in first 4 months of life in experimental groups
To demonstrate that growth from enrollment to age 4 months is equivalent between infants fed EXPL1 or EXPL2. This is measured by weight gain velocity (g/day).
Time frame: From enrollment to age 4 months
Gastrointestinal (GI) tolerance
GI tolerance assessed using the Infant Gastrointestinal Symptom Questionnaire (IGSQ). IGSQ scores range from 13 to 65, with lower scores indicating lower GI symptom burden.
Time frame: Enrollment and age 4, 6, and 12 months
Stooling pattern
Stool frequency and consistency assessed using a 3-day infant stool diary.
Time frame: Age 2 and 4 months
Atopic dermatitis severity
Atopic dermatitis severity assessed using the Patient Oriented Eczema Measure (POEM). POEM scores range from 0 to 28, with lower scores indicating lower atopic dermatitis severity.
Time frame: Enrollment and age 4, 6, and 12 months
Allergy-related symptoms
Allergy-related symptoms assessed using the Multi-Organ System Questionnaire for Infants (MOSQ-I). MOSQ-I scores range from 0 to 105, with lower scores indicating lower allergy-related symptom burden.
Time frame: Enrollment and age 4, 6, and 12 months
Dietary intake
Total energy and macronutrient intake calculated from food recalls / diaries
Time frame: Age 6 months
Weight
Weight (g)
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Length
Length (cm)
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Head circumference
Head circumference (cm)
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Weight-for-age z-score
Weight-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Weight-for-length z-score
Weight-for-length z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Length-for-age z-score
Length-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Head circumference-for-age z-score
Head circumference-for-age z-score based on World Health Organization (WHO) and Saudi Arabian growth charts.
Time frame: Enrollment and age 1, 2, 3, 4, and 6 months
Stool microbiota composition
Stool microbiota composition assessed using shotgun metagenomic analysis
Time frame: Age 4 months
Stool microbiota metabolism
Stool organic acids and other metabolites
Time frame: Age 4 months
Fecal peptides
Fecal milk-derived peptides
Time frame: Age 4 months
Urinary metabolomic profile
Untargeted analysis of urine metabolites by H1-nuclear magnetic resonance (NMR) spectroscopy
Time frame: Age 4 months
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société des Produits Nestlé (SPN) →